ERHSX Performance — Eaton Vance Worldwide Health Sciences Fund, Class R
Data updated: 2026-07-27
ERHSX returned −6.15% year to date and +5.43% over one year to May 2026. Annualised returns are +3.98% over 3 years and +3.01% over 5 years. The fund trailed its Global Health Care Equity category average: $100 invested three years ago grew to $112, against $126 for the category, and to $105 over one year, against $120. Volatility over the past three years was 13.24% a year. In the 12 months to May 2026 the fund lost a net $93.1M, and assets reached $757.90M.
ERHSX Growth of $100
What $100 invested in Eaton Vance Worldwide Health Sciences Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Global Health Care Equity category average over the same months.
| Period | ERHSX | Category average |
|---|---|---|
| 1 year (Jun 2025 – May 2026) | $105 | $120 |
| 3 years (Jun 2023 – May 2026) | $112 | $126 |
| 5 years (Jun 2021 – May 2026) | $116 | $103 |
| Since data start (Sep 2019 – May 2026) | $157 | $154 |
ERHSX Trailing Returns
Total returns to May 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | −6.15% |
| 1 year | +5.43% |
| 3 years (annualised) | +3.98% |
| 5 years (annualised) | +3.01% |
ERHSX Annual Returns
Calendar-year total returns of Eaton Vance Worldwide Health Sciences Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–May) | −6.15% |
| 2025 | +10.03% |
| 2024 | +3.21% |
| 2023 | +5.42% |
| 2022 | −9.64% |
| 2021 | +21.80% |
| 2020 | +12.75% |
| 2019 (Sep–Dec) | +12.58% |
ERHSX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.3% | +1.5% | −7.7% | −0.9% | +0.7% | — | — | — | — | — | — | — |
| 2025 | +6.6% | +1.2% | −4.1% | −1.8% | −3.6% | +1.0% | −4.0% | +4.8% | −0.4% | +3.5% | +7.6% | −0.4% |
| 2024 | +2.5% | +3.3% | +1.9% | −4.1% | +3.5% | +2.6% | +3.2% | +5.4% | −2.8% | −4.8% | −0.6% | −6.3% |
| 2023 | −0.5% | −3.8% | +4.0% | +3.6% | −3.1% | +2.9% | +1.3% | −0.6% | −3.8% | −4.3% | +6.1% | +4.4% |
| 2022 | −9.0% | +0.5% | +5.4% | −5.2% | −0.7% | −1.7% | +3.3% | −7.6% | −4.4% | +7.3% | +5.3% | −1.6% |
| 2021 | −0.4% | −1.4% | +2.1% | +4.2% | +2.0% | +2.7% | +3.4% | +3.3% | −5.8% | +6.7% | −4.4% | +8.4% |
| 2020 | −1.7% | −6.4% | −3.4% | +11.2% | +3.7% | −1.0% | +3.6% | +2.6% | −1.6% | −4.6% | +7.3% | +3.8% |
| 2019 | — | — | — | — | — | — | — | — | −0.7% | +4.3% | +4.6% | +3.9% |
ERHSX Risk
Risk measures from monthly returns over Jun 2023 – May 2026.
- 3-year volatility (annualised): 13.24%
- 3-year Sharpe ratio: -0.04 (vs 4.5% risk-free rate)
- Best month: +7.64% (Nov 2025)
- Worst month: −7.72% (Mar 2026)
ERHSX Fund Flows
Monthly money in and out of Eaton Vance Worldwide Health Sciences Fund, from SEC Form N-PORT.
- 12-month net flow: −$93.1M
- 12-month gross sales (incl. reinvestments): $125.2M
- Sales ÷ redemptions: 0.57×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| May 2026 | $8.8M | $19.6M | −$10.8M |
| Apr 2026 | $5.9M | $17.9M | −$12.0M |
| Mar 2026 | $11.3M | $21.1M | −$9.8M |
| Feb 2026 | $7.0M | $17.8M | −$10.8M |
| Jan 2026 | $7.1M | $18.0M | −$10.9M |
| Dec 2025 | $70.3M | $29.2M | $41.1M |
| Nov 2025 | $1.4M | $12.9M | −$11.5M |
| Oct 2025 | $2.3M | $16.8M | −$14.5M |
| Sep 2025 | $2.0M | $14.3M | −$12.3M |
| Aug 2025 | $2.1M | $18.1M | −$16.1M |
| Jul 2025 | $3.4M | $19.3M | −$15.9M |
| Jun 2025 | $3.6M | $13.3M | −$9.7M |
ERHSX Assets Under Management
Net assets of Eaton Vance Worldwide Health Sciences Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-05-31 | $757.90M |
| 2026-02-28 | $858.03M |
| 2025-11-30 | $885.22M |
| 2025-08-31 | $834.61M |
| 2025-05-31 | $861.68M |
| 2025-02-28 | $979.88M |
| 2024-11-30 | $1.01B |
| 2024-08-31 | $1.12B |
| 2024-05-31 | $1.02B |
| 2024-02-29 | $1.03B |
| 2023-11-30 | $953.53M |
| 2023-08-31 | $1.00B |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.